Phase I radioimmunotherapy with non-myeloablative doses of 90 Yttrium-labelled humanized MN-14 [labetuzumab Y-90] in advanced ovarian cancer
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 09 Jan 2007
At a glance
- Drugs Labetuzumab Y-90 (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 09 Jan 2007 New trial record.